Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8558010 | 0.86 | S1PR1 (0.41) | MAOAMAOB | |
| SCHEMBL75539 | 0.78 | HTR2A (0.43) | MAOAMAOBHTR2ADPP4 | |
| SCHEMBL7922095 | 0.77 | PARP10 (0.33) | — | |
| SCHEMBL865212 | 0.76 | ADRA2A (0.41) | KDM1AMAOAMAOBHTR2A | |
| SCHEMBL7920039 | 0.76 | PNMT (0.39) | KDM1A | |
| SCHEMBL4240413 | 0.74 | MME (0.42) | MAOAMAOBHDAC9MMEMMP8 | |
| SCHEMBL18091534 | 0.73 | ESR2 (0.35) | KDM1AHDAC9MMEDPP4MMP8 | |
| SCHEMBL3238183 | 0.73 | MAOA (0.65) | KDM1AMAOAMAOBMMP8 | |
| SCHEMBL6187762 | 0.73 | HTR2A (0.39) | KDM1AMAOAMAOBHTR2AHDAC9 | |
| SCHEMBL3238206 | 0.73 | HTR2A (0.35) | KDM1AMAOAMAOBHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-08-05 | — | — | US | disclosed |
| CN-111836807-A | Oxaspiro compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3527569-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA FOR USE IN TREATING DRYE EYE | Vitae Pharmaceuticals, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3102576-B1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20170260180-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-09-14 | — | — | US | disclosed |
| US-20170260180-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-09-14 | — | — | US | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| CN-1798559-A | Quinoline-2-one-derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2006-07-05 | — | — | CN | disclosed |
| US-20060041014-A1 | Treatment of male sexual dysfunction | PFIZER INC | 2006-02-23 | — | — | US | disclosed |
| EP-1613315-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087142-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020028799-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| EP-0640594-A1 | Hydantoin derivative as metalloprotease inhibitor | FUJIREBIO INC. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041014-A1 | Treatment of male sexual dysfunction | MME, PDE5A, PREP | KDM1A 1824/4885MAOA 247/4885MAOB 268/4885 |
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | KDM1A 2437/4885MAOA 4051/4885MAOB 3370/4885 |
| US-20020028799-A1 | Treatment of male sexual dysfunction | MME, PDE5A, PREP | KDM1A 1824/4885MAOA 247/4885MAOB 268/4885 |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | KDM1A 2842/4885MAOA 3773/4885MAOB 3088/4885 |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | KDM1A 2437/4885MAOA 4051/4885MAOB 3370/4885 |
| US-20170260180-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | KDM1A 2437/4885MAOA 4051/4885MAOB 3370/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | KDM1A 1587/4885MAOA 383/4885MAOB 544/4885 |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | KDM1A 2437/4885MAOA 4051/4885MAOB 3370/4885 |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | KDM1A 2895/4885MAOA 1176/4885MAOB 1058/4885 |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | KDM1A 2437/4885MAOA 4051/4885MAOB 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.